ClinicalTrials.gg
RecruitingNCT06149286OLYMPIA-5Updated Nov 12, 2026

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

A Phase 3 interventional study of Odronextamab and Lenalidomide in Relapsed/Refractory Follicular Lymphoma and Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL), sponsored by Regeneron Pharmaceuticals. Recruiting at 172 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 10 months later.
Updated Nov 12, 20262 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
580
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 194 studies testing rituximab in Lymphoma, Follicular — 12 open to participants now, 24 under way, 6 of them phase 3. Rituximab · Lymphoma, Follicular.

Planned enrollment
13th of 188
580 · median 48
Started
2023
with 4 others
Phase 3
35 of 194
2 open now
Primary completion
2031-04
later than 22 of 23 live
Registered
186th of 194
by date

Among the 194 studies testing rituximab in Lymphoma, Follicular, this one is the 13th largest by planned enrollment of the 188 interventional ones that give a count, is one of 5 that started in 2023, is one of 35 in phase 3, reaches primary completion later than 22 of the 23 other live ones, and was the 186th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

12 of the 194 studies testing rituximab in Lymphoma, Follicular are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies testing rituximab in Lymphoma, Follicular, or all of them as a file.
02

Study summary

This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's Lymphoma (NHL).

This study will be made up of two parts (Part 1 not randomized, Part 2 randomized - controlled).

The aim of Part 1 of the study is to see how safe and tolerable the study drug is when used in combination with lenalidomide, in participants with FL or MZL, and to determine the dose of the study drug to be used in Part 2 of this study. This combination is considered "first-in-human" as it has not been tested as a combination treatment in humans before.

The aim of Part 2, of the study is to assess how well the combination of the study drug and lenalidomide works compared to the combination of rituximab (called "the comparator drug") and lenalidomide. The combination of comparator drug and lenalidomide is the current standard-of-care treatment for relapsed/refractory FL and/or MZL. Standard-of-care means the usual medication expected and used when receiving treatment for a condition.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug in combination with lenalidomide
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
  • The impact from the study drug on quality-of-life and ability to complete routine daily activities
03

Conditions studied

  • Relapsed/Refractory Follicular Lymphoma
  • Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

Keywords

  • Relapsed/Refractory Follicular Lymphoma
  • Relapsed/Refractory Marginal Zone Lymphoma
  • Non-Hodgkin lymphomas
  • Indolent lymphomas
  • Odronextamab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Local histologic confirmation of FL grade 1-3a or MZL (nodal, splenic, or extra nodal MZL) as assessed by the investigator, as described in the protocol.
  2. Must have disease or relapsed after at least 1 prior line (with a duration of at least 2 cycles) of systemic chemo-immunotherapy or immunotherapy. Prior systemic therapy should have included at least one anti-Cluster of Differentiation 20 (CD20) monoclonal antibody, and participant should meet indication for treatment, as described in the protocol.
  3. Have on cross sectional imaging documented by diagnostic Computed Tomography [CT], or Magnetic Resonance Imaging [MRI] imaging, as described in the protocol.
  4. (ECOG) performance status of 0 to 2.
  5. Adequate hematologic and organ function, as described in the protocol.
  6. All study participants must:

    1. Have an understanding that lenalidomide could have a potential teratogenic risk.
    2. Agree to abstain from donating blood while taking study drug therapy and for 28 days after discontinuation of lenalidomide.
    3. Agree not to share study medication with another person.
    4. Agree to be counseled about pregnancy precautions and risk of fetal exposure associated with lenalidomide.

Key Exclusion Criteria:

  1. Primary Central Nervous System (CNS) lymphoma or known involvement (either current or prior history of CNS involvement) by non-primary CNS NHL, as described in the protocol.
  2. Participants with current or past histological evidence of high-grade or diffuse large B-cell lymphoma, or any histology other than FL grade 1-3a or MZL.
  3. History of or current relevant CNS pathology, as described in the protocol.
  4. A other than NHL (inclusion diagnosis) unless the participant is adequately and definitively treated and is cancer free for at least 3 years, with the exception of localized prostate cancer treated with hormone therapy or local radiotherapy (ie, pellets), cervical carcinoma in situ, breast cancer in situ, or nonmelanoma skin cancer that was definitively treated.
  5. Any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol.
  6. Allergy/ to study drugs or . as described in the protocol.
  7. Active infection as defined in the protocol.

Note: Other protocol-defined Inclusion/Exclusion criteria apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
580 participants (estimated)

Study arms

  • Experimental
    Odronextamab+Lenalidomide

    In part 1 (safety run-in), participants with R/R indolent lymphoma (FL and MZL), will receive odronextamab in combination with lenalidomide. In part 2, 1:1 randomized participants with R/R FL and MZL, will receive odronextamab in combination with lenalidomide.

    Drug: Odronextamab · Drug: Lenalidomide

  • Experimental
    Rituximab+Lenalidomide

    In part 2 only, 1:1 randomized participants with R/R FL and ML, will receive rituximab in combination with lenalidomide (R2) followed by lenalidomide monotherapy.

    Drug: Lenalidomide · Drug: Rituximab

Interventions

  • Administered per the protocol

    Also known as: REGN1979, Ordspono

  • Administered per the protocol

    Also known as: REVLIMID

  • Administered per the protocol

    Also known as: Rituxan

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities (DLTs) for odronextamab in combination with lenalidomide

    Part 1

    Time frame: Up to 35 days

  2. Incidence of Treatment Emergent Adverse Events (TEAEs) for odronextamab in combination with lenalidomide

    Part 1

    Time frame: Up to 2 years

  3. Severity of TEAEs for odronextamab in combination with lenalidomide

    Part 1

    Time frame: Up to 2 years

  4. Progression-Free Survival (PFS) as assessed by Independent Central Review (ICR)

    Part 2

    Time frame: Up to 5 years

Secondary outcomes

  1. Odronextamab concentrations in serum

    Part 1 and Part 2

    Time frame: Up to 30 months

  2. Incidence of Anti-Drug Antibodies (ADA) to odronextamab

    Part 1 and Part 2

    Time frame: Up to 30 months

  3. Magnitude of ADAs to odronextamab

    Part 1 and Part 2

    Time frame: Up to 30 months

  4. Best Overall Response (BOR) as assessed by investigator review

    Part 1 and Part 2

    Time frame: Up to 30 months

  5. Duration of Response (DOR) as assessed by investigator review

    Part 1 and Part 2

    Time frame: Up to 5 years

  6. PFS as assessed by investigator review

    Part 1 and Part 2

    Time frame: Up to 5 years

  7. Complete Response (CR) as assessed by ICR

    Part 2

    Time frame: Up to 30 months

  8. BOR as assessed by ICR

    Part 2

    Time frame: Up to 30 months

  9. Overall Survival (OS)

    Part 2

    Time frame: Up to 5 years

  10. Event Free Survival (EFS) as assessed by ICR

    Part 2

    Time frame: Up to 5 years

  11. EFS as assessed by local investigator review

    Part 2

    Time frame: Up to 5 years

  12. DOR as assessed by ICR

    Part 2

    Time frame: Up to 5 years

  13. Time To Next anti-lymphoma Treatment (TTNT)

    Part 2

    Time frame: Up to 5 years

  14. Incidence of TEAEs for odronextamab in combination with lenalidomide versus R2

    Part 2

    Time frame: Up to 2 years

  15. Severity of TEAEs for odronextamab in combination with lenalidomide versus R2

    Part 2

    Time frame: Up to 2 years

  16. Overall change in Patient Reported Outcomes (PROs) as measured by scores of European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQC30)

    Part 2 The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a Global Health Status (GHS)/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and GHS/QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden.

    Time frame: Up to 5 years

  17. Overall change in PROs as measured by scores of Functional Assessment of Cancer Therapy-Lymphoma Subscale (FACT-LymS)

    Part 2 The FACT-Lym Lymphoma Subscale (LymS) includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life.

    Time frame: Up to 5 years

  18. Overall change in PROs as measured by scores of EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L)

    Part 2 The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ Visual Analogue Scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state".

    Time frame: Up to 5 years

  19. Change from first assessment in Patient Global Impression on Severity (PGIS)

    Part 2 The PGIS includes a single-item to assess how a patient perceives the overall severity of cancer symptoms over the past 7 days. Patients will choose the response that best describes the severity of their overall cancer symptoms with options on a 5-point scale ranging from 1 (No symptoms) to 4 (Very Severe).

    Time frame: Up to 5 years

  20. Change from first assessment in Patient Global Impression on Change (PGIC)

    Part 2 The PGIC item includes a single-item to assess how a patient perceives their overall change in health status since the start of study treatment. Patients will choose from response options on a 7-point scale ranging from 1 (Much Better) to 7 (Much worse); 1- Much Better, 2-Moderately Better, 3-A Little Better, 4-About the Same, 5-A Little Worse, 6-Moderately Worse, 7-Much Worse.

    Time frame: Up to 5 years

  21. Change from first assessment in the Global Population item 5 (GP5) items of the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire

    Part 2 A single item (GP5) of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4).

    Time frame: Up to 5 years

07

Study locations

168 of 172 sites recruiting

Showing the first 100 of 172 sites across 18 countries. Choose a country and city above to see the rest.

08

References and documents

Related links

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Apr 2031, 88 months after the start.

Of 45 industry-sponsored phase 3 interventional studies under Lymphoma, Follicular, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 86. This study's planned 88 months is above that.

Counting every sponsor, half of 80 studies reached it within 63 months; a quarter within 36 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2023
First posted
Nov 28, 2023
StartActual
Dec 28, 2023
Primary completionEst.
Apr 30, 2031
CompletionEst.
Apr 30, 2031
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (1 Poland, 1 United States)
  • Aidport Sp. z o.o. · Skorzewo, Poland
  • East Carolina University · Greenville, United States
Show 1 removed
  • Aidport · Skorzewo, Poland
across 2 updates, Oct 7, 2026 – Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    1 site added
    Show site
    • East Carolina University · Greenville, United States
    + 1 other change: verification date
  2. Oct 7, 2026
    1 site added, 1 site removed
    Show site
    • Aidport Sp. z o.o. · Skorzewo, Poland
    Show 1 removed
    • Aidport · Skorzewo, Poland
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06149286
Responsible party
Sponsor
First posted
Nov 28, 2023
Start date
Dec 28, 2023
Primary completion
Apr 30, 2031 (estimated)
Completion
Apr 30, 2031 (estimated)
Last update
Nov 12, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Odronextamab · Rituximab

Start the discussion